Boston Scientific (NYSE:BSX) had its price target lowered by analysts at Truist Financial Corporation from $130.00 to $120.00. They now have a "buy" rating on the stock.
Boston Scientific (NYSE:BSX) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Boston Scientific (NYSE:BSX) was given a new $131.00 price target on by analysts at Canaccord Genuity Group Inc..
AVeta Medical Appoints Karen Noblett as New CEO [Yahoo! Finance]
Boston Scientific (NYSE:BSX) had its price target raised by analysts at Royal Bank Of Canada from $125.00 to $130.00. They now have an "outperform" rating on the stock.